Investors aiming for above-average returns often turn to the practice of stock picking. Skillful choices in individual stocks can be a catalyst for substantial wealth growth.
The price of Akebia Therapeutics Inc (NASDAQ: AKBA) closed at $3.84 in the last session, down -0.52% from day before closing price of $3.86. In other words, the price has decreased by -$0.52 from its previous closing price. On the day, 2.55 million shares were traded. AKBA stock price reached its highest trading level at $3.935 during the session, while it also had its lowest trading level at $3.77.
Ratios:
We take a closer look at AKBA’s different ratios to gain a better understanding of the stock. For the most recent quarter (mrq), Quick Ratio is recorded 2.02 and its Current Ratio is at 2.23. In the meantime, Its Debt-to-Equity ratio is 8.39 whereas as Long-Term Debt/Eq ratio is at 7.41.
On April 28, 2025, Leerink Partners started tracking the stock assigning a Outperform rating and target price of $7.
On April 01, 2025, Jefferies started tracking the stock assigning a Buy rating and target price of $6.Jefferies initiated its Buy rating on April 01, 2025, with a $6 target price.
Insider Transactions:
An investor can also benefit from insider trades by learning what management is thinking about the future direction of stock prices. A recent insider transaction in this stock occurred on Jun 30 ’25 when Ostrowski Erik sold 41,314 shares for $3.67 per share. The transaction valued at 151,622 led to the insider holds 503,586 shares of the business.
Ostrowski Erik bought 41,314 shares of AKBA for $151,622 on Jun 30 ’25. On Jun 09 ’25, another insider, Malabre Richard C, who serves as the SVP, Chief Accounting Officer of the company, sold 15,000 shares for $4.01 each. As a result, the insider received 60,150 and left with 266,914 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, AKBA now has a Market Capitalization of 1013775360 and an Enterprise Value of 1038216448. For the stock, the TTM Price-to-Sale (P/S) ratio is 5.45 while its Price-to-Book (P/B) ratio in mrq is 40.87. Its current Enterprise Value per Revenue stands at 5.615 whereas that against EBITDA is 101.766.
Stock Price History:
The Beta on a monthly basis for AKBA is 0.97, which has changed by 1.7971015 over the last 52 weeks, in comparison to a change of 0.13161862 over the same period for the S&P500. Over the past 52 weeks, AKBA has reached a high of $4.08, while it has fallen to a 52-week low of $1.07. The 50-Day Moving Average of the stock is 12.96%, while the 200-Day Moving Average is calculated to be 67.93%.
Shares Statistics:
According to the various share statistics, AKBA traded on average about 4.71M shares per day over the past 3-months and 3064290 shares per day over the past 10 days. A total of 261.64M shares are outstanding, with a floating share count of 251.62M. Insiders hold about 4.19% of the company’s shares, while institutions hold 36.62% stake in the company. Shares short for AKBA as of 1749772800 were 18498837 with a Short Ratio of 5.41, compared to 1747267200 on 19722763. Therefore, it implies a Short% of Shares Outstanding of 18498837 and a Short% of Float of 7.12.
Dividends & Splits
Against a Trailing Annual Dividend Yield of 0.0
